New Zealand markets open in 8 hours 5 minutes

Anebulo Pharmaceuticals, Inc. (ANEB)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
2.1000-0.0800 (-3.67%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 54.46M
Enterprise value 49.31M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)10.92
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) -1.10
52-week change 3-2.78%
S&P500 52-week change 323.76%
52-week high 34.0500
52-week low 31.6200
50-day moving average 32.5245
200-day moving average 32.5568

Share statistics

Avg vol (3-month) 34.94k
Avg vol (10-day) 32.73k
Shares outstanding 525.93M
Implied shares outstanding 625.93M
Float 83.91M
% held by insiders 165.38%
% held by institutions 128.17%
Shares short (15 May 2024) 46.19k
Short ratio (15 May 2024) 41.09
Short % of float (15 May 2024) 40.15%
Short % of shares outstanding (15 May 2024) 40.02%
Shares short (prior month 15 Apr 2024) 420.12k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Jun 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-57.90%
Return on equity (ttm)-104.28%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA N/A
Net income avi to common (ttm)-9.35M
Diluted EPS (ttm)-0.3700
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)5.15M
Total cash per share (mrq)0.2
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)5.32
Book value per share (mrq)0.19

Cash flow statement

Operating cash flow (ttm)-8.89M
Levered free cash flow (ttm)-5.51M